Using a novel Birc5+/- MYCN tg/+ NB mouse model, we show that even a specific, i.e., genetic, and marked inhibition of survivin transcription was insufficient to inhibit NB growth, in contrast to the efficacy of YM155 we observed in vitro. The gene discussed is MYCN; the disease is neuroblastoma.